Effects of bronchodilators on dynamic hyperinflation following hyperventilation in patients with COPD

Respirology

Volumn 12, Issue 1, 2007, Pages 93-99

  Fujimoto, Keisaku ^a   Yoshiike, Fumiaki ^a   Yasuo, Masanori ^a   Kitaguchi, Yoshiaki ^a   Urushihata, Kazuhisa ^a   Kubo, Keishi ^a   Honda, Takayuki ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Air trapping; Bronchodilator; COPD; Hyperventilation; Lung hyperinflation

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CARBON MONOXIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; SHORT ACTING DRUG;

ADULT; AGED; ARTICLE; BREATHING DEPTH; BREATHING RATE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; FORCED EXPIRATORY VOLUME; HUMAN; HYPERINFLATION; HYPERVENTILATION; INSPIRATORY CAPACITY; LINEAR REGRESSION ANALYSIS; LUNG VOLUME; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SAMPLE SIZE; SMOKING; THERAPY EFFECT; TIDAL VOLUME; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, INHALATION; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; DISEASE PROGRESSION; FORCED EXPIRATORY VOLUME; HUMANS; HYPERVENTILATION; MALE; MIDDLE AGED; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 33845715562     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2006.00963.x     Document Type: Article

References (22)

1. O'Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. Am. Rev. Respir. Dis. 1993; 148: 1351-7.
2. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 770-7.
3. O'Donnell DE, D'Arsigny C, Fitzpatrick M, Webb KA. Exercise hypercapnia in advanced chronic obstructive pulmonary disease: the role of lung hyperinflation. Am. J. Respir. Crit. Care Med. 2002; 166: 663-8.
4. Diaz O, Villafranca C, Ghezzo H et al. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur. Respir. J. 2000; 16: 269-75.
5. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1996; 153: 967-75.
6. Dodd DS, Brancatisano T, Engel LA. Chest wall mechanics during exercise in patients with severe chronic airflow obstruction. Am. Rev. Respir. Dis. 1984; 12: 33-8.
7. Stubbing DG, Pengelly LD, Morse JLC et al. Pulmonary mechanics during exercise in subjects with chronic airflow obstruction. J. Appl. Physiol. 1980; 49: 511-15.
8. Duranti R, Filippelli M, Bianchi R et al. Inspiratory capacity and decrease in lung hyperinflation with albuterol in COPD. Chest 2002; 122: 2009-14.
9. O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 158: 1557-65.
10. O'Donnell DE, Fluge T, Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur. Respir. J. 2004; 23: 832-40.
11. Man WDC, Mustfa N, Nikoletou D et al. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax 2004; 59: 471-6.
12. Gelb AF, Gutierrez CA, Weisman IM, Newsom R, Taylor CF, Zamel N. Simplified detection of dynamic hyperinflation. Chest 2004; 126: 1855-60.
13. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI Workshop Report. Bethesda, National Heart, Lung and Blood Institute, 2001. Update of the Management Sections, GOLD website (www.goldcopd.com). Data updated: 1 July 2003.
14. The Japanese Respiratory Society. Spirometry, Flow-Volume Curve, Diffusion Capacity of the Lung. The Japanese Respiratory Society, Tokyo, 2004.
15. Nishida O, Kambe M, Sewake N et al. Pulmonary function in healthy subjects and its prediction: 5. Pulmonary diffusing capacity in adults. Jpn. J. Clin. Pathol. 1976; 24: 941-7.
16. Boren HG, Kory RC, Syner LC et al. The veterans administration-army cooperative study of pulmonary function. 2. The lung volume and its subdivisions in normal men. Am. J. Med. 1966; 41: 96-101.
17. Kubo K, Eda S, Yamamoto H et al. Expiratory and inspiratory chest computed tomography and pulmonary function tests in cigarette smokers. Eur. Respir. J. 1999; 13: 252-6.
18. O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur. Respir. J. 2004; 24: 86-94.
19. Boni E, Corda L, Franchini D et al. Volume effect and exertional dyspnoea after bronchodilator in patients with COPD with and without expiratory flow limitation at rest. Thorax 2002; 57: 528-32.
20. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160: 542-9.
21. Brusasco V, Hodder R, Miravitlles M et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399-404.
22. Donohue JF, van Noord JA, Bateman ED et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55.